Location Directory

Clinical trials in Tampa, Florida

This page shows live ClinicalTrials.gov search results for Tampa, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9115

Shown on this page

Current sort

Institutions in Tampa

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Moffitt Cancer Center

Live official records

Open in full search

Conditions: Migraine
Interventions: MEDI0618, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 34
States / cities: Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 27 more

Conditions: Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Advanced Solid Tumors
Interventions: LY4337713; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 20
States / cities: Newport Beach, California • Stanford, California • Miami, Florida + 14 more

Conditions: Myeloproliferative Neoplasms (MPNs)
Interventions: DMR-001, Ruxolitinib; Drug
Lead sponsor: Damora Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 25
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 20 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Pridopidine, Placebo; Drug
Lead sponsor: Prilenia; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 18
States / cities: Phoenix, Arizona • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Acute Treatment of Migraine
Interventions: Rimegepant (PF-07899801); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 115
States / cities: Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more

Conditions: Cannabis Withdrawal
Interventions: PP-01, Nabilone, Placebo; Combination Product · Drug
Lead sponsor: PleoPharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 22
States / cities: Little Rock, Arkansas • Rogers, Arkansas • New Haven, Connecticut + 19 more

Conditions: Plaque Psoriasis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more

Conditions: Pediatric Migraine
Interventions: Rimegepant/BHV3000, Matching placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 2,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 169
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more

Conditions: Multiple Sclerosis (MS) Primary Progressive
Interventions: Orelabrutinib, Placebo; Drug
Lead sponsor: Zenas BioPharma (USA), LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 19
States / cities: Pheonix, Arizona • Scottsdale, Arizona • West Hollywood, California + 15 more

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Atezolizumab, Etoposide, Carboplatin, Lurbinectedin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 12
States / cities: New Haven, Connecticut • Gainesville, Florida • Ocala, Florida + 9 more

Conditions: B Acute Lymphoblastic Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin, Doxorubicin, Echocardiography Test, Imatinib, Leucovorin, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Prednisone, Radiation Therapy, Thioguanine, Vincristine; Procedure · Biological · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 366 Days to 46 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 145
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 121 more

Conditions: Incontinence-associated Dermatitis, Decubitus Ulcer
Interventions: Dynamic Oxygen Skin Therapy (DOST), Standard Wound Care; Device · Other
Lead sponsor: RashEndZ Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Clinical trials in Tampa, Florida

Filter and sort this location

Institutions in Tampa

Live official records

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Safety and Efficacy of RashEndZ Wound Aeration Technology